Table10_A cuproptosis-related lncRNAs signature for prognosis, chemotherapy, and immune checkpoint blockade therapy of low-grade glioma.XLSX

Cuproptosis is a new type of cell death that is associated with mitochondrial respiration of the tricarboxylic acid cycle. Previous studies showed that long non-coding RNAs (lncRNAs) regulated low-grade glioma (LGG) progression. However, the potential applications of cuproptosis-related lncRNAs (CRLs) in LGG were not explored. A comprehensive analysis was performed in The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) cohorts. We first screened two distinct cuproptosis subtypes based on prognostic CRLs using consensus clustering. To facilitate individualized survival prediction in LGG, we constructed a prognostic signature (including CRNDE, HAR1A, and FAM181A-AS1) in the TCGA dataset. The prognostic signature exhibited excellent predictive ability and reliability, which was validated in the CGGA_325 and CGGA_693 datasets. Notably, patients in the high-risk group had increased immune cell infiltration and expression of immune checkpoints, which indicated that they may benefit more from immune checkpoint blockade (ICB) therapy. Finally, the prognostic signature screened the population with sensitivity to chemotherapy and ICB therapy. In summary, this study initially explored the mechanism of CRLs in LGG and provides some insights into chemotherapy and ICB therapy of LGG.

铜死亡（Cuproptosis）是一种与三羧酸循环线粒体呼吸过程相关的新型细胞死亡方式。既往研究表明，长链非编码RNA（long non-coding RNAs，简称lncRNAs）可调控低级别胶质瘤（low-grade glioma，简称LGG）的进展。然而，铜死亡相关长链非编码RNA（cuproptosis-related lncRNAs，简称CRLs）在低级别胶质瘤中的潜在应用价值尚未得到探索。本研究在癌症基因组图谱（The Cancer Genome Atlas，简称TCGA）队列与中国胶质瘤基因组图谱（Chinese Glioma Genome Atlas，简称CGGA）中开展了全面分析。本研究首先基于预后相关CRLs，通过共识聚类算法筛选出两种不同的铜死亡亚型。为实现低级别胶质瘤患者的个体化生存预测，本研究在TCGA数据集中构建了一项预后特征（包含CRNDE、HAR1A及FAM181A-AS1）。该预后特征展现出优异的预测性能与可靠性，并在CGGA_325与CGGA_693数据集中得到了验证。值得注意的是，高危组患者的免疫细胞浸润程度与免疫检查点表达水平均显著升高，提示该组患者可能从免疫检查点阻断（immune checkpoint blockade，简称ICB）治疗中获益更多。此外，该预后特征可筛选出对化疗及ICB治疗敏感的患者群体。综上，本研究首次探索了CRLs在低级别胶质瘤中的作用机制，可为低级别胶质瘤的化疗及ICB治疗提供新的研究思路。